Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has prepared detailed reports on more than 1,000 companies [1]

[Q1 2025 Performance Overview](index=2&type=section&id=Q1%202025%20Performance%20Overview) Novo Nordisk reported strong Q1 2025 sales growth driven by GLP-1 treatments, but revised its full-year outlook downwards due to US compounded GLP-1 impact, while advancing key R&D milestones Q1 2025 Financial Highlights (vs. Q1 2024) | PROFIT AND LOSS | Q1 2025 (DKK million) | Q1 2024 (DKK million) | Growth as reported | Growth at CER* | | --- | --- | --- | --- | --- | | Net sales | 78,087 | 65,349 | 19 % | 18 % | | Operating profit | 38,791 | 31,846 | 22 % | 20 % | | Net profit | 29,034 | 25,407 | 14 % | N/A | | Diluted earnings per share (in DKK) | 6.53 | 5.68 | 15 % | N/A | *CER: Constant exchange rates - The full-year outlook was reduced due to lower-than-planned branded GLP-1 penetration in the US, impacted by rapid compounding expansion, with the company actively working to prevent unlawful compounding[6](index=6&type=chunk) - Key R&D advancements include completing the pivotal trial for **CagriSema** for obesity and filing for US approval of **oral semaglutide 25 mg**, a potential first-in-class oral GLP-1 treatment[6](index=6&type=chunk)[7](index=7&type=chunk) [Strategic Aspirations and Performance Highlights](index=3&type=section&id=Strategic%20Aspirations%20and%20Performance%20Highlights) The company tracks Q1 2025 performance against strategic goals, achieving **65% CER growth in Obesity care sales** but experiencing a slight decline in Diabetes market share and a **37% increase in CO2e emissions** Q1 2025 Performance vs. Strategic Aspirations | Category | Aspiration | Q1 2025 Performance | |---|---|---| | **Commercial** | Strengthen diabetes leadership to >1/3 | Diabetes value market share declined to 33.3% | | | > DKK 25B in Obesity care sales by 2025 | Obesity care sales grew 65% (CER) to DKK 18.4B | | | Sustained growth for Rare Disease | Rare disease sales grew 3% (CER) to DKK 4.6B | | **Financials** | Solid sales and operating profit growth | Sales grew 18% (CER), Operating profit grew 20% (CER) | - Key innovation milestones in Q1 include the successful **REDEFINE 2 trial** for **CagriSema**, regulatory submission of **oral semaglutide 25 mg** for weight management, and in-licensing of a **GLP-1/GIP/Glucagon triple agonist**[15](index=15&type=chunk) - ESG highlights include a **37% increase in CO2e emissions** compared to Q1 2024, an increase in women in senior leadership to **42%**, and providing medical treatment to **43.1 million** people with diabetes and **2.6 million** with obesity[9](index=9&type=chunk)[10](index=10&type=chunk)[11](index=11&type=chunk) [Commercial Execution](index=5&type=section&id=Commercial%20Execution) Commercial execution highlights strong sales growth across regions and therapeutic areas, driven by GLP-1 treatments, despite challenges from compounded products and supply constraints [Geographic Sales Development](index=5&type=section&id=Geographic%20Sales%20Development) Overall sales grew **18% at CER**, with strong performance across all regions, driven by significant growth in Obesity care in both US and International Operations Sales Growth by Geographical Area (Q1 2025) | Geographical Area | Sales (DKK million) | Growth at CER | |---|---|---| | **US Operations** | 44,316 | 17 % | | **International Operations** | 33,771 | 19 % | | - EUCAN | 14,765 | 13 % | | - Emerging Markets | 8,790 | 24 % | | - APAC | 4,594 | 25 % | | - Region China | 5,622 | 22 % | | **Total Sales** | **78,087** | **18 %** | - US Operations growth was driven by a **40% CER increase in Obesity care sales** and a **10% CER increase in GLP-1 diabetes sales**, though growth was negatively impacted by compounded GLP-1s[21](index=21&type=chunk) - International Operations growth was driven by a **137% CER increase in Obesity care sales** and a **13% CER increase in GLP-1 diabetes sales**, with growth affected by periodic supply constraints[22](index=22&type=chunk) [Sales Development by Therapeutic Area](index=7&type=section&id=Sales%20Development%20by%20Therapeutic%20Area) Sales growth was primarily driven by the Diabetes and Obesity care segment, which grew **19% at CER**, led by **65% CER growth in Obesity care sales** from Wegovy® Sales by Therapeutic Area (Q1 2025 vs Q1 2024) | Therapy Area | Sales Q1 2025 (DKK million) | Growth at CER | |---|---|---| | **Diabetes and Obesity care total** | 73,468 | 19 % | | - Total GLP-1 (Diabetes) | 39,574 | 11 % | | - Total Insulin | 14,997 | 3 % | | - Total Obesity care | 18,424 | 65 % | | **Rare disease total** | 4,619 | 3 % | | **Total Sales** | **78,087** | **18 %** | [Diabetes Care](index=8&type=section&id=Diabetes%20Care) Diabetes care sales rose **8% at CER to DKK 55.0 billion**, driven by GLP-1 products, despite a slight decrease in global diabetes value market share to **33.3%** Global Diabetes Care Sales & Market Share | Metric | Feb 2025 | Feb 2024 | Q1 2025 Sales (DKK M) | Q1 2025 Growth (CER) | |---|---|---|---|---| | **Total Diabetes Care** | 33.3% | 33.9% | 55,044 | 8% | | **GLP-1 Diabetes** | 54.0% | 55.3% | 39,574 | 11% | | **Insulin (Volume Share)** | 43.5% | 45.1% | 14,997 | 3% | - **Ozempic® sales grew 15% at CER to DKK 32.7 billion**, while **Rybelsus® sales grew 13% at CER**, and **Victoza® sales declined by 46%** as the market shifts to once-weekly treatments[36](index=36&type=chunk) [Obesity Care](index=13&type=section&id=Obesity%20Care) Obesity care sales surged **65% at CER to DKK 18.4 billion**, primarily driven by Wegovy®, despite the impact of compounded GLP-1s on US uptake Obesity Care Sales Growth (Q1 2025, CER) | Geographical Area | Sales Growth (CER) | |---|---| | Global | 65 % | | US Operations | 40 % | | International Operations | 137 % | - **Wegovy® sales increased by 83% at CER**, while **Saxenda® sales decreased by 35% at CER** as the market moves to more effective once-weekly treatments[52](index=52&type=chunk) - In the US, the volume of compounded GLP-1s is estimated to have **negatively impacted Wegovy® prescription uptake**, with Novo Nordisk actively focused on preventing unlawful compounding and expanding patient access[52](index=52&type=chunk)[53](index=53&type=chunk) [Rare Disease](index=17&type=section&id=Rare%20Disease) Rare disease sales increased **3% at CER to DKK 4.6 billion**, driven by rare endocrine disorders, while rare blood disorder products saw a slight decline Rare Disease Sales Growth (Q1 2025, CER) | Geographical Area | Sales Growth (CER) | |---|---| | Global | 3 % | | US Operations | 1 % | | International Operations | 5 % | - Sales of **rare endocrine disorder products grew 14% at CER**, while **rare blood disorder products decreased by 1% at CER**[58](index=58&type=chunk) [Financials](index=4&type=section&id=Financials) The company's financial performance is detailed, highlighting significant increases in net sales, operating profit, and free cash flow, alongside changes in gross margin and cost structures [Financial Highlights for Q1 2025](index=4&type=section&id=Financial%20Highlights%20for%20Q1%202025) Novo Nordisk achieved a **19% increase in net sales** and a **22% rise in operating profit** in Q1 2025, alongside a slight gross margin contraction and significant increases in capital expenditure Detailed Financial Highlights (Q1 2025 vs Q1 2024) | Metric | Q1 2025 | Q1 2024 | % Change | |---|---|---|---| | Net sales (DKK M) | 78,087 | 65,349 | 19% | | Gross margin | 83.5% | 84.8% | -1.3pp | | Operating profit (DKK M) | 38,791 | 31,846 | 22% | | Operating margin | 49.7% | 48.7% | +1.0pp | | Net profit (DKK M) | 29,034 | 25,407 | 14% | | Diluted EPS (DKK) | 6.53 | 5.68 | 15% | | Capital expenditure (DKK M) | 13,422 | 8,474 | 58% | | Free cash flow (DKK M) | 9,492 | 5,020 | 89% | [Development in Costs and Operating Profit](index=18&type=section&id=Development%20in%20Costs%20and%20Operating%20Profit) Operating profit grew **20% at CER to DKK 38.8 billion**, despite a gross margin decline due to acquisitions and capacity expansion, and increased R&D costs - Gross margin declined to **83.5%** from **84.8%** YoY, reflecting amortisations and depreciations related to Catalent and costs for ongoing capacity expansions[65](index=65&type=chunk) - Sales and distribution costs increased by **10% at CER**, driven by promotional activities for Wegovy® and Ozempic®[66](index=66&type=chunk) - R&D costs increased by **19% at CER**, mainly due to increased late-stage clinical trial activity and early research activities within Obesity care[66](index=66&type=chunk) [Cash Flow and Capital Allocation](index=19&type=section&id=Cash%20Flow%20and%20Capital%20Allocation) The company's cash flow generation and capital allocation strategy are detailed, emphasizing significant investments in capacity expansion and the decision to forgo a share buyback program [Free Cash Flow and Capital Expenditure](index=19&type=section&id=Free%20Cash%20Flow%20and%20Capital%20Expenditure) Free cash flow increased **89% to DKK 9.5 billion** in Q1 2025, despite a **58% increase in capital expenditure** for capacity expansion, leading to no share buyback program in 2025 Cash Flow and CAPEX (Q1 2025 vs Q1 2024) | Metric (DKK billion) | Q1 2025 | Q1 2024 | |---|---|---| | Free cash flow | 9.5 | 5.0 | | Capital expenditure (PP&E) | 13.4 | 8.5 | - Capital expenditure primarily reflects investments in **additional capacity for API production and fill-finish capacity** for current and future products[74](index=74&type=chunk) - Due to the significant increase in CAPEX investments in 2025, Novo Nordisk is **not conducting a share buyback programme**[77](index=77&type=chunk) [2025 Outlook](index=20&type=section&id=2025%20Outlook) The company's 2025 financial guidance has been updated, reflecting revised sales and operating profit growth projections and free cash flow forecasts due to market dynamics [Updated 2025 Financial Guidance](index=20&type=section&id=Updated%202025%20Financial%20Guidance) Novo Nordisk has lowered its full-year 2025 guidance for sales, operating profit, and free cash flow due to compounded GLP-1s in the US, while capital expenditure expectations remain unchanged 2025 Outlook Revision (at CER) | Metric | New Outlook (May 7, 2025) | Old Outlook (Feb 5, 2025) | |---|---|---| | Sales growth | 13% to 21% | 16% to 24% | | Operating profit growth | 16% to 24% | 19% to 27% | | Free cash flow (bDKK) | 56 to 66 | 75 to 85 | - The updated sales outlook reflects **lower-than-planned penetration of branded GLP-1 treatments** in the US, impacted by compounded GLP-1s[79](index=79&type=chunk) - The outlook assumes a **reduction in patients on compounded GLP-1 treatment** during the second half of 2025, following the FDA's removal of semaglutide injectables from the drug shortage list[80](index=80&type=chunk) - Capital expenditure is still expected to be around **DKK 65 billion** in 2025, reflecting the expansion of the global supply chain[83](index=83&type=chunk) [Innovation and R&D](index=23&type=section&id=Innovation%20and%20R%26D) Key advancements in the company's R&D pipeline and business development activities are highlighted, including pivotal trial results, new regulatory submissions, and expanded early-stage programs [Pipeline and Business Development](index=23&type=section&id=Pipeline%20and%20Business%20Development) The R&D pipeline saw significant progress with successful trials for CagriSema, key regulatory submissions for oral semaglutide and MASH treatment, and expansion of the early-stage obesity pipeline through new licensing agreements - The **REDEFINE 2 trial for CagriSema** demonstrated a superior **15.7% weight loss** in adults with obesity or overweight and type 2 diabetes[92](index=92&type=chunk) - Key regulatory submissions include **oral semaglutide 25 mg** for weight management in the US and **once-weekly semaglutide 2.4 mg for MASH** in both the EU and US, with the latter granted **priority review by the FDA**[93](index=93&type=chunk)[94](index=94&type=chunk) - Business development activities included exclusive license agreements for **UBT251**, a **GLP-1/GIP/glucagon triple receptor agonist**, and **LX9851**, an **oral non-incretin candidate** for obesity[98](index=98&type=chunk)[99](index=99&type=chunk) [Purpose and Sustainability (ESG)](index=26&type=section&id=Purpose%20and%20Sustainability%20%28ESG%29) The company's environmental and social performance is detailed, including increased CO2e emissions due to acquisitions, expanded patient reach, and growth in employee numbers and female leadership representation [Environmental and Social Performance](index=26&type=section&id=Environmental%20and%20Social%20Performance) Total CO2e emissions increased **37% YoY** due to acquisitions and investments, while patient reach expanded to **45.7 million**, and women in senior leadership rose to **42%** ESG Performance Highlights (Q1 2025 vs Q1 2024) | Metric | Q1 2025 | Q1 2024 | % Change | |---|---|---|---| | Total CO2e emissions (1,000 tonnes) | 667 | 486 | 37% | | Total patients reached (millions) | 45.7 | 41.8 | 9% | | Total employees (FTEs) | 77,406 | 66,015 | 17% | | Women in senior leadership | 42% | 41% | +1pp | - The increase in CO2e emissions was mainly driven by the **acquisition of new production sites**, **increased consumption of natural gas**, and **use of non-renewable electricity** at these new sites[103](index=103&type=chunk) - The number of full-time employees increased by **17%**, mainly driven by Product Supply and the acquisition of Catalent, which accounted for around **3,000 employees**[110](index=110&type=chunk) [Corporate Governance and Legal Matters](index=28&type=section&id=Corporate%20Governance%20and%20Legal%20Matters) Recent changes in corporate governance, including executive management reorganization, and updates on ongoing legal matters concerning compounded GLP-1 products are detailed [Corporate Governance](index=28&type=section&id=Corporate%20Governance) Significant changes in Executive Management were announced in April 2025, involving a reorganization of roles and responsibilities following a key departure - **Key changes in Executive Management** were implemented in April 2025 following the departure of the EVP of Commercial Strategy & Corporate Affairs[114](index=114&type=chunk) - The changes include promotions and shifts in responsibility for **Ludovic Helfgott** (Product & Portfolio Strategy), **Thilde Hummel Bøgebjerg** (Quality, IT & Environmental Affairs), and **Tania Sabroe** (People & Organisation and Global Communication)[114](index=114&type=chunk)[115](index=115&type=chunk) [Legal Matters](index=29&type=section&id=Legal%20Matters) The company is involved in litigation regarding the FDA's semaglutide shortage resolution, with a federal court denying a preliminary injunction sought by compounding organizations, ending enforcement discretion for 503A pharmacies - Novo Nordisk is involved in **litigation regarding the FDA's resolution of the semaglutide injectables shortage** and the subsequent allowance of compounding[117](index=117&type=chunk) - A US federal court **denied a motion for a preliminary injunction** filed by compounding-related organizations, **ending the period of enforcement discretion for 503A compounding pharmacies** on April 24[117](index=117&type=chunk) [Financial Statements and Appendices](index=30&type=section&id=Financial%20Statements%20and%20Appendices) This section provides detailed financial statements and appendices, including unaudited condensed financial statements and reconciliations for non-IFRS measures [Detailed Financial Data](index=33&type=section&id=Detailed%20Financial%20Data) The appendices provide detailed financial information, including unaudited condensed financial statements, reconciliations for non-IFRS measures, and restated 2024 sales data by new geographical reporting structure - **Appendix 2** provides the detailed **Income Statement** and **Statement of Comprehensive Income** for Q1 2025[134](index=134&type=chunk) - **Appendix 7** provides definitions and reconciliations for **non-IFRS financial measures** used in the report, such as Net sales at CER, EBITDA, and Free cash flow[141](index=141&type=chunk) - **Appendix 8** provides a detailed **restatement of sales data for 2024**, broken down by the **new geographical areas** (US Operations and International Operations, which includes EUCAN, Emerging Markets, APAC, and Region China)[152](index=152&type=chunk)[153](index=153&type=chunk)

Analyst's Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

Core Insights - Novo Nordisk reported a better-than-expected net profit of 29.03 billion Danish kroner ($4.4 billion) for the three-month period ending March, surpassing analyst expectations of 27.8 billion Danish kroner [2] - The company lowered its full-year sales growth forecast to 13% to 21% at constant exchange rates, down from the previous forecast of 16% to 24% [3] Financial Performance - Sales of the Wegovy obesity drug reached 17.36 billion Danish kroner, slightly below the anticipated 18.51 billion Danish kroner [2] - Overall revenues for the company were reported at 78.09 billion Danish kroner, marginally below the expected 78.18 billion Danish kroner [3] Market Dynamics - The company faces increased competition in the weight loss drug market, with rivals such as Roche, AstraZeneca, and AbbVie developing new candidates [4] - Negative sentiment persists due to disappointing trial results for Novo's next-generation obesity drug candidate, CagriSema [4] Competitor Landscape - Eli Lilly, a key U.S. competitor, reported a 45% rise in first-quarter sales, although revenues for its weight-loss drug Zepbound were slightly lower than expected due to reduced drug pricing [5]

Core Viewpoint - Hims & Hers Health Inc. is positioned as a potential disruptor in the healthcare sector, combining traditional medicine with telehealth innovations, leading to significant user growth and financial performance [2][4][10]. Company Performance - The company reported active users reaching 2.4 million, reflecting a net growth rate of 38% over the past year [5]. - Hims & Hers achieved a net revenue growth of 111% year-over-year, totaling $586 million [6]. - The gross profit margin stands at an attractive 73%, allowing for substantial capital retention from sales [7]. - Free cash flow reached a record $50.1 million, nearly five times the previous year's $11.9 million [8]. - The return on invested capital (ROIC) is reported at 24.6%, indicating strong potential for long-term value compounding [9]. Market Dynamics - The company secured a collaboration deal with Novo Nordisk, enhancing its revenue streams and industry recognition [10]. - Institutional investors contributed $739 million in capital over the past quarter, with an additional $86 million in the current quarter, signaling strong market confidence [11]. - Approximately 33.3% of Hims & Hers shares are held in short positions, creating potential for a "short squeeze" if the stock rallies [12]. - Analysts may adjust their valuations and ratings in response to the company's growth, potentially leading to upward pressure on the stock price [13].

Core Viewpoint - Novo Resources Corp. has released an updated corporate presentation highlighting its strategic priorities, exploration results, project advancements, and near-term catalysts, providing investors with insights into its growth strategy and gold asset portfolio [1][2]. Group 1: Strategic Priorities and Exploration - The updated corporate presentation reflects significant progress in Novo's exploration portfolio, emphasizing the company's focus on disciplined growth and long-term shareholder value [2]. - Novo is an Australian gold explorer with a land package of approximately 5,500 square kilometers in the Pilbara region and an additional 22 square kilometers in the Bendigo Tectonic Zone of Victoria, targeting standalone gold projects with over 1 million ounces (Moz) development potential [2]. Group 2: Key Projects and Joint Ventures - The Egina Gold Camp in the Pilbara is a key project area, where De Grey Mining is forming a joint venture at the Becher Project through an exploration expenditure of A$25 million over four years for a 50% interest, with geological similarities to De Grey's 12.7 Moz Hemi Project [3]. - Novo is advancing gold exploration south of Becher in the Egina Gold Camp as part of the Croydon joint venture, where Novo holds a 70% interest [3]. - A lithium joint venture with SQM in the Pilbara has been established, providing shareholders with exposure to battery metals [4]. Group 3: Recent Additions to Portfolio - Novo has strengthened its exploration portfolio by adding the TechGen John Bull Gold Project in New South Wales and the Manhattan Tibooburra Gold Project in the Albert Goldfields, both of which show potential for significant discovery and align with the company's strategy of identifying projects with over 1 Moz gold potential [5]. - These high-grade gold projects complement the landholding consolidation that forms the Toolunga Project in the Onslow District of Western Australia [5]. Group 4: Investment Strategy - Novo has a significant investment portfolio and a disciplined program to identify value-accretive opportunities aimed at building further value for shareholders [6].

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April. Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. A potential rival drops out For a relatively young, clinical-stage company, Viking has developed quite a high profile. That's because its leading drug candidate, VK2735, is its possible entry i ...

Summary of Key Points from the Conference Call on China Healthcare Equities Industry Overview - The conference focused on the **China Healthcare sector**, particularly the impact of US tariffs on the pharmaceutical supply chain and related industries [2][21]. Core Insights - **Tariff Impact Ranking**: The impact of tariffs is expected to be highest on medical consumables, followed by devices and drugs [2]. - **Timeline for Tariffs**: Tariffs on US pharmaceutical imports may commence within one to two months due to ongoing investigations [2]. - **Impact on Exporters**: Small and medium-sized exporters of low-end medical consumables are anticipated to be most affected, with major CDMOs like Wuxi AppTec, Pharmaron, and Genscript facing 30-50% revenue exposure to the US [2][21]. - **Risk Management**: Large companies are managing risks through planned production capacity shifts to ASEAN/Europe and maintaining high inventory levels (two to three years) [2]. - **API Exporters**: The risk for API exporters is considered manageable in the short term due to China's established supply chain role, despite having double-digit US revenue exposure [2]. Financial Projections - **Revenue and Profit Margin Erosion**: Scenario analysis indicates potential revenue and net profit margin erosion of approximately 5% and 1 percentage point across sub-sectors due to tariffs [3]. - **CDMO Impact**: CDMOs could see up to a 6% revenue impact and a 5-10% decrease in net profit margins [3]. - **Cost Inflation**: Import-dependent segments, such as IVD reagents, may experience around 1% cost inflation, slightly squeezing margins [3]. Market Dynamics - **Global Supply Chain Shifts**: The global supply chain is shifting, but short-term offsets are expected due to stockpiling [2]. - **Domestic Substitution**: There is an expectation of accelerating domestic substitution in the MedTech sector due to import weaknesses caused by tariffs [9]. - **Market Concentration**: A higher level of market concentration is anticipated in the MedTech subsector [9]. Company-Specific Insights - **Limited US Exposure**: Chinese innovative drugs are forecasted to have almost no sales exposure to the US, with limited impact from R&D cost increases due to higher export prices [7]. - **CDMO Resilience**: CDMOs are expected to manage tariff impacts effectively, with 80% of tariff expenses potentially passed through to US clients [8]. - **MedTech Companies**: Companies like Mindray and United Imaging are expected to face low single-digit cost impacts due to their low US exposure [9]. Export Data - **China Healthcare Exports**: Total exports from the China Healthcare sector reached **USD 107.99 billion** in 2024, marking a **5.8% year-on-year increase** [15]. - **Export Composition**: APIs accounted for approximately **40%** of total exports, while IVDs made up **21%** [15][18]. Conclusion - The China Healthcare sector is navigating potential tariff impacts with strategic adjustments and risk management practices. While certain sub-sectors may face challenges, the overall resilience of the industry, particularly in API production and innovative drug development, is expected to mitigate significant adverse effects.

Shares of Hims & Hers Health fell 5% in extended trading on Monday after the company reported first-quarter earnings that beat analysts' expectations but offered weaker-than-expected guidance.Here's how the company did:Earnings per share: 20 cents vs. 12 cents expected by LSEGRevenue: $586 million vs. $538 million expected by LSEGRevenue at the telehealth company increased 111% in the first quarter from $278.2 million during the same period last year, according to a release. Hims & Hers reported a net incom ...

Core Insights - Novo Resources Corp. is preparing for a drilling campaign at the John Bull Gold Project, with a planned ~1,500 m RC drilling program set to commence in June 2025, pending drill rig availability and governmental approvals [2][8][18] - Recent exploration activities have identified exceptional drill targets, including a large gold system associated with a porphyry in the southwest portion of the John Bull tenement [2][7][10] - The exploration campaign has significantly enhanced the understanding of the mineral system, supporting the presence of an Intrusion Related Gold System (IRGS) model [7][10][12] Exploration Details - The John Bull Gold Project is located in the New England District of NSW, covering approximately 32 sq km and is known for hosting multiple gold and polymetallic mineral systems [4][39] - Recent mapping and sampling have extended the known gold anomaly to ~1.5 km strike with peak soil results of 1.59 g/t Au and rock chip samples returning peak results of 67.9 g/t Au [7][19] - Four key targets have been identified for the upcoming drilling program, focusing on areas with high-order soil anomalies and dense sheeted quartz vein occurrences [8][17] Historical Context - Historical mining at John Bull included hydraulic sluicing and several shafts, with previous soil sampling by TechGen revealing a significant gold anomaly over 900 m long and 250 m wide at > 100 ppb Au [19][20] - TechGen completed 17 RC holes for 2,249.5 m, with peak results from shallow drilling including grades of up to 67.9 g/t Au [20][24] Future Work - Following the initial drilling program, further exploration activities will include infill and extensional drill testing, diamond drilling, and potential geophysical surveys targeting porphyry-related systems [30][34] - The company is also advancing exploration at other projects, including the Balla Balla and Tibooburra Gold Projects, with results pending [30][39]